Bioxcel therapeutics reports first quarter 2024 financial results

Advancing tranquility and serenity program plans for two pivotal phase 3 trials to expand bxcl501 market potential in acute treatment of agitation

BTAI Ratings Summary

BTAI Quant Ranking